ATE554186T1 - Eph-b4 spezifische sirna zur reduktion von epo- induziertem tumorzellwachstum während anämiebehandlung in krebspatienten, gewebeschutz- erythropoietin-rezeptor (nepor) und verfahren zu seiner verwendung - Google Patents

Eph-b4 spezifische sirna zur reduktion von epo- induziertem tumorzellwachstum während anämiebehandlung in krebspatienten, gewebeschutz- erythropoietin-rezeptor (nepor) und verfahren zu seiner verwendung

Info

Publication number
ATE554186T1
ATE554186T1 AT08854346T AT08854346T ATE554186T1 AT E554186 T1 ATE554186 T1 AT E554186T1 AT 08854346 T AT08854346 T AT 08854346T AT 08854346 T AT08854346 T AT 08854346T AT E554186 T1 ATE554186 T1 AT E554186T1
Authority
AT
Austria
Prior art keywords
nepor
epo
erythropoietin
disclosed
eph
Prior art date
Application number
AT08854346T
Other languages
English (en)
Inventor
David Jackson
Martin Stein
Hartmut Voss
Stephan Brock
Christopher Danes
Anil Sood
Original Assignee
Molecular Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Health Gmbh filed Critical Molecular Health Gmbh
Application granted granted Critical
Publication of ATE554186T1 publication Critical patent/ATE554186T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/746—Erythropoetin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT08854346T 2007-11-29 2008-11-28 Eph-b4 spezifische sirna zur reduktion von epo- induziertem tumorzellwachstum während anämiebehandlung in krebspatienten, gewebeschutz- erythropoietin-rezeptor (nepor) und verfahren zu seiner verwendung ATE554186T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99104207P 2007-11-29 2007-11-29
PCT/EP2008/066480 WO2009068677A1 (en) 2007-11-29 2008-11-28 Novel tissue protective erythropoietin receptor (nepor) and methods of use

Publications (1)

Publication Number Publication Date
ATE554186T1 true ATE554186T1 (de) 2012-05-15

Family

ID=40370571

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08854346T ATE554186T1 (de) 2007-11-29 2008-11-28 Eph-b4 spezifische sirna zur reduktion von epo- induziertem tumorzellwachstum während anämiebehandlung in krebspatienten, gewebeschutz- erythropoietin-rezeptor (nepor) und verfahren zu seiner verwendung

Country Status (12)

Country Link
EP (3) EP2960341B1 (de)
AT (1) ATE554186T1 (de)
AU (1) AU2008328754B2 (de)
CA (2) CA2706994C (de)
DK (1) DK2492355T3 (de)
ES (2) ES2542033T3 (de)
HR (1) HRP20150733T1 (de)
HU (1) HUE026591T2 (de)
PL (1) PL2492355T3 (de)
PT (1) PT2492355E (de)
SI (1) SI2492355T1 (de)
WO (1) WO2009068677A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE035655T2 (en) 2005-08-05 2018-05-28 Araim Pharmaceuticals Inc Tissue protective peptides and their use
SI2056845T1 (en) 2006-08-08 2018-02-28 Rheinische Friedrich-Wilhelms-Universitaet Bonn STRUCTURE AND USE 5 'PHOSPHATE OF OLIGONUCLEOTES
US8357501B2 (en) * 2007-11-29 2013-01-22 Molecular Health Gmbh Tissue protective erythropoietin receptor (NEPOR) and methods of use
EP2297323A1 (de) 2008-05-21 2011-03-23 Hartmann, Gunther 5 -triphosphat-oligonukleotid mit stumpfem ende und verwendugen davon
US20130210030A1 (en) * 2010-07-19 2013-08-15 Cellzome Ag In vivo method for the evaluation of a compound-target interaction
EP2508530A1 (de) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags
MY166974A (en) * 2011-06-15 2018-07-27 Hoffmann La Roche Anti-human epo receptor antibodies and method of use
EP2712870A1 (de) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Neuartige RIG-I-Liganden und Herstellungsverfahren dafür
AU2014290116A1 (en) * 2013-07-17 2016-02-11 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
CN116769054A (zh) 2016-02-05 2023-09-19 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
US11753463B2 (en) 2016-05-13 2023-09-12 Orionis Biosciences BV Therapeutic targeting of non-cellular structures
US11236141B2 (en) 2016-05-13 2022-02-01 Orionis Biosciences BV Targeted mutant interferon-beta and uses thereof
JP7204643B2 (ja) 2016-10-24 2023-01-16 オリオニス バイオサイエンシズ ビーブイ 標的変異インターフェロン－ガンマおよびその使用
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
MX2019009255A (es) 2017-02-06 2019-11-05 Orionis Biosciences Nv Proteínas quiméricas dirigidas y sus usos.
CN112074267B (zh) 2018-02-05 2024-06-28 奥里尼斯生物科学公司股份有限公司 成纤维细胞结合剂及其用途
JP7773372B2 (ja) 2019-03-28 2025-11-19 オリオニス バイオサイエンシズ，インコーポレイテッド 線維芽細胞活性化タンパク質結合物質およびその使用
CN111175519B (zh) * 2020-01-09 2020-11-27 浙江大学 Epo在制备肝细胞癌tace疗效评估试剂中的应用
WO2022054748A1 (ja) * 2020-09-10 2022-03-17 扶桑薬品工業株式会社 エリスロポエチンシグナル伝達阻害タンパク質

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002951409A0 (en) * 2002-09-16 2002-09-26 North Western Adelaide Health Services Methods for regulating cancer
EP1606305A4 (de) * 2003-03-12 2009-06-24 Vasgene Therapeutics Inc Nukleinsäureverbindungen für die inhibierung von angiogenese und tumorwachstum
US7381410B2 (en) * 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
US7718363B2 (en) * 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
EP1799867A2 (de) * 2004-09-23 2007-06-27 Vasgene Therapeutics, Inc. Zusammensetzungen und verfahren zur erkennung und behandlung von tumoren

Also Published As

Publication number Publication date
SI2492355T1 (sl) 2015-08-31
HUE026591T2 (hu) 2016-06-28
EP2960341A1 (de) 2015-12-30
DK2492355T3 (da) 2015-07-13
EP2109690A1 (de) 2009-10-21
WO2009068677A1 (en) 2009-06-04
EP2109690B1 (de) 2012-04-18
CA2802984C (en) 2016-04-12
AU2008328754A1 (en) 2009-06-04
ES2386495T3 (es) 2012-08-21
EP2960341B1 (de) 2018-06-27
CA2706994C (en) 2013-03-12
HRP20150733T1 (hr) 2015-08-14
AU2008328754B2 (en) 2015-04-16
EP2492355B1 (de) 2015-04-08
CA2706994A1 (en) 2009-06-04
PT2492355E (pt) 2015-09-10
PL2492355T3 (pl) 2015-09-30
EP2109690B9 (de) 2012-10-24
CA2802984A1 (en) 2009-06-04
ES2542033T3 (es) 2015-07-29
EP2492355A1 (de) 2012-08-29

Similar Documents

Publication Publication Date Title
SI2492355T1 (sl) Tkivno protektivni eritropoetinski receptor (nepor) in postopki uporabe
Pascual et al. Dietary palmitic acid promotes a prometastatic memory via Schwann cells
EP2531598A4 (de) Whsc1 und whsc1l1 für zielgene zur krebstherapie und -diagnose
Marcuzzo et al. Altered miRNA expression is associated with neuronal fate in G93A-SOD1 ependymal stem progenitor cells
Ronchi et al. ErbB2 receptor over-expression improves post-traumatic peripheral nerve regeneration in adult mice
Kimura et al. Tumor-homing effect of human mesenchymal stem cells in a TH-MYCN mouse model of neuroblastoma
Abdullah et al. Proliferation rate of stem cells derived from human dental pulp and identification of differentially expressed genes
Kim et al. MicroRNA-34a regulates migration of chondroblast and IL-1β-induced degeneration of chondrocytes by targeting EphA5
MXPA05014220A (es) Genes regulados en cancer ovarico como objetivos de pronostico y terapeuticos.
Griner et al. Aggressive myeloid leukemia formation is directed by the Musashi 2/Numb pathway
Chen et al. Hypoxia stimulates proliferation of rat neural stem/progenitor cells by regulating mir-21: an in vitro study
Kim et al. Derivation of neural stem cells from human teratomas
Luo et al. TM4SF19-AS1 facilitates the proliferation of lung squamous cell carcinoma by recruiting WDR5 to mediate TM4SF19
Liu et al. Interaction between stromal cells and tumor cells promotes GCB-DLBCL cell survival via the CD40/RANK-KDM6B-NF-κB axis
WO2005083086A3 (en) Epha4 as therapeutic target of prc and pdaca
Wu et al. Protein phosphatase 2A regulatory subunit B56β modulates erythroid differentiation
Marqués-García et al. p73 plays a role in erythroid differentiation through GATA1 induction
Assadollahi et al. Comparison of Oct4, Sox2 and Nanog expression in pancreatic cancer cell lines and human pancreatic tumor
Aggarwal et al. Meningioma cell reprogramming and microenvironment interactions underlie brain invasion
Schachter et al. Expression of kinase genes in primary hyperparathyroidism: adenoma versus hyperplastic parathyroid tissue
Hang et al. TET3 Protein Represses Proliferation of the MG-63 Human Osteosarcoma Cell Line by Regulating DNA Demethylation: an Epigenetic Study
Gening et al. Expression profiles of serum long non-coding RNA in ovarian cancer patients receiving platinum-containing chemotherapy
Yalim-Camci et al. Dual high expression of epithelial-mesenchymal transcription factors ZEB1 and ELF3 was inversely correlated with survival of liver cancer patients
Moolsuwan et al. Dopachrome tautomerase is a retinoblastoma-specific gene, and its proximal promoter is preferentially active in human retinoblastoma cells
Mondal et al. 18P Trastuzumab in HER2-amplified or overexpressed gallbladder cancer: Experience from an Indian cancer center